Skip to main content
logo
INBIOGEN Co., Ltd. (KRX:101140)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,030.00
-320.00 (-5.98%)
At close: Aug 3, 2026

INBIOGEN Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
5,4446,2977,0416,24110,42010,481
Revenue Growth
-25.55%-10.57%12.82%-40.11%-0.58%2.57%
Gross Profit
-516.42-384.38628.511,3081,9721,829
Operating Income
-3,991-4,333-6,087-6,164-5,969-8,146
Net Income
-18,128-1,41916,12211,344-117,21894,125
Earnings Per Share
--1614.691333.01-32327.5331498.90
EPS Growth
--21.13%---

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3,533901.75,7166,0899,29023,152
Total Debt
4,1081,168894.79593.261,77413,410
Net Cash (Debt)
-575.79-266.074,8215,4967,5159,742
Net Cash Growth
---12.27%-26.87%-22.85%-86.88%
Net Cash Per Share
--482.88645.772072.633260.05

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-4,293-5,554-33.13-1,051-11,505-7,069
Capital Expenditures
-10.1-42.5-84.28-25.96-130.68-2,360
Free Cash Flow
-4,303-5,597-117.41-1,077-11,636-9,430
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-9.49%-6.10%8.93%20.95%18.93%17.45%
Operating Margin
-73.31%-68.81%-86.45%-98.77%-57.29%-77.73%
Pretax Margin
-333.01%-22.53%228.98%190.02%-1285.11%1059.69%
Profit Margin
-333.01%-22.53%228.98%181.77%-1124.99%898.07%
FCF Margin
-79.05%-88.88%-1.67%-17.25%-111.67%-89.97%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--5.788.23-1.98
PS Ratio
9.2316.6313.2514.954.9517.78